<DOC>
	<DOCNO>NCT00520390</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose EZN-2208 give patient advanced cancer lymphoma . The safety study drug effect disease also study . Enzon also perform pharmacokinetic ( PK ) test EZN-2208 . PK test measure amount drug body different time point .</brief_summary>
	<brief_title>A Phase I , Study Evaluate Safety Tolerability Intravenous EZN-2208 Patients With Advanced Solid Tumors Lymphoma ( EZN-2208-02 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance and/or metastatic solid tumor lymphoma refractory standard therapy Measurable evaluable disease Score 0 2 ECOG performance scale Concurrent serious medical illness Known , clinically suspect , history central nervous system ( CNS ) tumor involvement Active diarrhea Known history coagulation disorder Patients require cytochrome P450 3A4 ( CYP3A4 ) enzyme induce medication Requirement ketoconazole strong inhibitor CYP3A4 enzymes Prior chemotherapy , immunotherapy , investigational agent , therapy use treat cancer within 4 week ( 6 week prior treatment mitomycin C nitrosoureas ) prior schedule administration EZN2208 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>